Registry Study for Optimal Management of Liver Failure in the Chinese Population

Condition(s) studied

Investigational drug(s) / intervention(s)

ALF: Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks

SALF: The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks

ACLF: On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period

Study summary

Liver failure is the most severe form of liver damage caused by viral, alcoholic, drug-related and ischemia-reperfusion factors, often combined with extrahepatic organ damage, resulting in a high mortality rate. This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics, epidemiology of bacterial and fungal infections, the impact of sarcopenia on clinical prognosis, and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure. The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection, end-stage liver disease combined with organ failure, and early warning of critically ill patients.

Eligibility

Primary outcome measure(s)

• Overall survival — 28-day
  28-day survival rates without liver transplantation
• Overall survival — 90-day
  90-day survival rates without liver transplantation

Trial sites (14)

More First Affiliated Hospital Xi'an Jiaotong University trials in China

Other trials for the same condition